FAQ on Clene Inc. CEO's Presentation at Investor Summit Virtual

What is the main topic of the presentation by Clene Inc.’s CEO?

The main topic is an update on Clene Inc.’s progress and strategic outlook, particularly focusing on its late clinical-stage biopharmaceutical developments for neurodegenerative diseases.

When and where is the Investor Summit Virtual taking place?

The Investor Summit Virtual is taking place on June 10, and it is an online event.

Who is presenting at the Investor Summit Virtual for Clene Inc.?

Rob Etherington, the CEO and President of Clene Inc., will be presenting.

What is Clene Inc.’s focus in the biopharmaceutical field?

Clene Inc. focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

What is CNM-Au8® and its significance?

CNM-Au8® is an investigational first-in-class therapy by Clene Nanomedicine Inc. that targets mitochondrial function and the NAD pathway to improve central nervous system cells’ survival and function, reducing oxidative stress.

Where can I find more information about Clene Inc.?

More information is available on Clene Inc.’s website at www.Clene.com and in the company’s newsroom at https://ibn.fm/CLNN.

What is InvestorWire and its role?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication and a range of corporate communications solutions to enhance brand awareness and reach a wide audience.

How can I view the full press release about Clene Inc.’s presentation?

The full press release can be viewed at https://ibn.fm/Eu8nA.